Pistacia lentiscus oleoresin: Virtual screening and identification of masticadienonic and isomasticadienonic acids as inhibitors of 11 β -hydroxysteroid dehydrogenase 1

Planta Medica

Volumn 81, Issue 6, 2015, Pages 525-532

  Vuorinen, Anna ^a   Seibert, Julia ^b   Papageorgiou, Vassilios P ^c   Rollinger, Judith M ^d   Odermatt, Alex ^b   Schuster, Daniela ^a   Assimopoulou, Andreana N ^c  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY OF BASEL   (Switzerland)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

11 hydroxysteroid dehydrogenase; Anacardiaceae; antidiabetic; diabetes; Pistacia lentiscus; virtual screening

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; ENZYME INHIBITOR; MASTICADIENONIC ACID; OLEORESINS; PLANT EXTRACT; TRITERPENE;

ANTAGONISTS AND INHIBITORS; CHEMISTRY; HEK293 CELL LINE; HUMAN; ISOLATION AND PURIFICATION; ISOMERISM; PISTACIA;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ENZYME INHIBITORS; HEK293 CELLS; HUMANS; ISOMERISM; PISTACIA; PLANT EXTRACTS; TRITERPENES;

EID: 84940009285     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0035-1545720     Document Type: Article

References (45)

1. Browicz K. Pistacia lentiscus cv. chia (Anacardiaceae) on Chios island. Plant Syst Evol: 1987; 155 189 195
2. Assimopoulou A. N., Papageorgiou V. P. Oleoresins from Pistacia species: chemistry and biology. In: Govil J. N., Singh V. K., Siddiqui N. T. editors Recent progress in medicinal plants natural product II. Houston Studium Press, LLC: 2007; 145 202
3. Bozorgi M., Memariani Z., Mobli M., Salehi Surmaghi M. H., Shams-Ardekani M. R., Rahimi R. Five Pistacia species (P. vera, P. atlantica, P. terebinthus, P. khinjuk, and P. lentiscus): a review of their traditional uses, phytochemistry, and pharmacology. TheScientificWorldJo: 2013; 2013 1 33
4. Assimopoulou A. N., Papageorgiou V. P. GC-MS analysis of penta- and tetra-cyclic triterpenes from resins of Pistacia species. Part I. Pistacia lentiscus var. chia. Biomed Chromatogr: 2005; 19 285 311
5. Rang H. P., Dale M. M., Ritter J. M., Moore P. K. The endocrine pancreas and the control of blood glucose. In: Hunter L. editor Pharmacology. 5th edition. London Churchill Livingstone: 2003; 380 393
6. Berger J., Moller D. E. The mechanisms of action of PPARs. Annu Rev Med: 2002; 53 409 435
7. Petersen R. K., Christensen K. B., Assimopoulou A. N., Fretté X., Papageorgiou V. P., Kristiansen K., Kouskoumvekaki I. Pharmacophore-driven identification of PPAR γ agonists from natural sources. J Comput Aided Mol Des: 2011; 25 107 116
8. Kokolakis A. K. Analysis and study of the biological activity of the constituents of the resin from the plant Pistacia lentiscus var. chia (Chios mastic gum) [Master Thesis]. Heraklion University of Crete: 2008
9. Georgiadis I., Karatzas T., Korou L. M., Agrogiannis G., Vlachos I. S., Pantopoulou A., Tzanetakou I. P., Katsilambros N., Perrea D. N. Evaluation of Chios mastic gum on lipid and glucose metabolism in diabetic mice. J Med Food: 2014; 17 393 399
10. Rang H. P., Dale M. M., Ritter J. M., Moore P. K. The pituitary and adrenal cortex. In: Hunter L. editor Pharmacology. 5th edition. London Churchill Livingstone: 2003; 409 427
11. Krozowski Z. The 11 β -hydroxysteroid dehydrogenases: functions and physiological effects. Mol Cell Endocrinol: 1999; 151 121 127
12. Atanasov A. G., Nashev L. G., Schweizer R. AS, Frick C., Odermatt A. Hexose-6-phosphate dehydrogenase determines the reaction direction of 11 β -hydroxysteroid dehydrogenase type 1 as an oxoreductase. FEBS Lett: 2004; 571 129 133
13. Bánhegyi G., Benedetti A., Fulceri R., Senesi S. Cooperativity between 11 β -hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase in the lumen of the endoplasmic reticulum. J Biol Chem: 2004; 279 27017 27021
14. Arnold P., Tam S., Yan L., Baker M. E., Frey F. J., Odermatt A. Glutamate-115 renders specificity of human 11 β -hydroxysteroid dehydrogenase type 2 for the cofactor NAD+. Mol Cell Endocrinol: 2003; 201 177 187
15. Ricketts M. L., Verhaeg J. M., Bujalska I., Howie A. J., Rainey W. E., Stewart P. M. Immunohistochemical localization of type 1 11 β -hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab: 1998; 83 1325 1335
16. Odermatt A., Kratschmar D. V. Tissue-specific modulation of mineralocorticoid receptor function by 11 β -hydroxysteroid dehydrogenases: An overview. Mol Cell Endocrinol: 2012; 350 168 186
17. Gathercole L. L., Lavery G. G., Morgan S. A., Cooper M. S., Sinclair A. J., Tomlinson J. W., Stewart P. M. 11 β -Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects. Endocr Rev: 2013; 34 525 555
18. Grundy S. M. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol: 2008; 28 629 636
19. Masuzaki H., Paterson J., Shinyama H., Morton N. M., Mullins J. J., Seckl J. R., Flier J. S. A transgenic model of visceral obesity and the metabolic syndrome. Science: 2001; 294 2166 2170
20. Paterson J. M., Morton N. M., Fievet C., Kenyon C. J., Holmes M. C., Staels B., Seckl J. R., Mullins J. J. Metabolic syndrome without obesity: Hepatic overexpression of 11 β -hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A: 2004; 101 7088 7093
21. Kotelevtsev Y., Holmes M. C., Burchell A., Houston P. M., Schmoll D., Jamieson P., Best R., Brown R., Edwards C. RW, Seckl J. R., Mullins J. J. 11 β -Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci U S A: 1997; 94 14924 14929
22. Hermanowski-Vosatka A., Balkovec J. M., Cheng K., Chen H. Y., Hernandez M., Koo G. C., Le Grand C. B., Li Z., Metzger J. M., Mundt S. S., Noonan H., Nunes C. N., Olson S. H., Pikounis B., Ren N., Robertson N., Schaeffer J. M., Shah K., Springer M. S., Strack A. M., Strowski M., Wu K., Wu T., Xiao J., Zhang B. B., Wright S. D., Thieringer R. 11 β -HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med: 2005; 202 517 527
23. Kotelevtsev Y., Brown R. W., Fleming S., Kenyon C., Edwards C. RW, Seckl J. R., Mullins J. J. Hypertension in mice lacking 11 β -hydroxysteroid dehydrogenase type 2. J Clin Invest: 1999; 103 683 689
24. Barf T., Vallgårda J., Emond R., Häggström C., Kurz G., Nygren A., Larwood V., Mosialou E., Axelsson K., Olsson R., Engblom L., Edling N., Rönquist-Nii Y., Öhman B., Alberts P., Abrahmsén L. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11 β -hydroxysteroid dehydrogenase type 1. J Med Chem: 2002; 45 3813 3815
25. Xu Z., Tice C. M., Zhao W., Cacatian S., Ye Y. J., Singh S. B., Lindblom P., McKeever B. M., Krosky P. M., Kruk B. A., Berbaum J., Harrison R. K., Johnson J. A., Bukhtiyarov Y., Panemangalore R., Scott B. B., Zhao Y., Bruno J. G., Togias J., Guo J., Guo R., Carroll P. J., McGeehan G. M., Zhuang L., He W., Claremon D. A. Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11 β -hydroxysteroid dehydrogenase type 1. J Med Chem: 2011; 54 6050 6062
26. Böhme T., Engel C. K., Farjot G., Güssregen S., Haack T., Tschank G., Ritter K. 1,1-Dioxo-5,6-dihydro-[4,1,2]oxathiazines, a novel class of 11 β -HSD1 inhibitors for the treatment of diabetes. Bioorg Med Chem Lett: 2013; 23 4685 4691
27. Rollinger J. M., Kratschmar D. V., Schuster D., Pfisterer P. H., Gumy C., Aubry E. M., Brandstötter S., Stuppner H., Wolber G., Odermatt A. 11 β -Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational approaches. Bioorg Med Chem: 2010; 18 1507 1515
28. Kratschmar D. V., Vuorinen A., Da Cunha T., Wolber G., Classen-Houben D., Doblhoff O., Schuster D., Odermatt A. Characterization of activity and binding mode of glycyrrhetinic acid derivatives inhibiting 11 β -hydroxysteroid dehydrogenase type 2. J Steroid Biochem Mol Biol: 2011; 125 129 142
29. Rollinger J. M., Stuppner H., Langer T. Virtual screening for the discovery of bioactive natural products. Prog Drug Res: 2008; 65 213 249
30. Wolber G., Rollinger J. M. Virtual screening and target fishing for natural products using 3D pharmacophores. In: Jacoby E. editor Computational chemogenomics. Boca Raton Pan Stanford Publishing: 2013; 117 139
31. Wermuth C. G., Ganellin C. R., Lindberg P., Mitscher L. A. Glossary of terms used in medicinal chemistry (IUPAC Recommendations). Pure Appl Chem: 1998; 70 1129 1143
32. Schuster D., Maurer E. M., Laggner C., Nashev L. G., Wilckens T., Langer T., Odermatt A. The discovery of new 11 β -hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening. J Med Chem: 2006; 49 3454 3466
33. Vuorinen A., Nashev L. G., Odermatt A., Rollinger J. M., Schuster D. Pharmacophore model refinement for 11 β -hydroxysteroid dehydrogenase inhibitors: search for modulators of intracellular glucocorticoid concentrations. Mol Inf: 2014; 33 15 25
34. Rollinger J. M., Steindl T. M., Schuster D., Kirchmair J., Anrain K., Ellmerer E. P., Langer T., Stuppner H., Wutzler P., Schmidtke M. Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein. J Med Chem: 2008; 51 842 851
35. Papageorgiou V. P., Bakola-Christianopoulou M. N., Apazidou K. K., Psarros E. E. Gas chromatographic-mass spectroscopic analysis of the acidic triterpenic fraction of mastic gum. J Chromatogr A: 1997; 769 263 273
36. Ramírez-Espinosa J. J., García-Jiménez S., Rios M. Y., Medina-Franco J. L., López-Vallejo F., Webster S. P., Binnie M., Ibarra-Barajas M., Ortiz-Andrade R., Estrada-Soto S. Antihyperglycemic and sub-chronic antidiabetic actions of morolic and moronic acids, in vitro and in silico inhibition of 11 β -HSD 1. Phytomedicine: 2013; 20 571 576
37. Blum A., Favia A. D., Maser E. 11 β -Hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds. Mol Cell Endocrinol: 2009; 301 132 136
38. Hu G. X., Lin H., Lian Q. Q., Zhou S. H., Guo J., Zhou H. Y., Chu Y., Ge R. S. Curcumin as a potent and selective inhibitor of 11 β -hydroxysteroid dehydrogenase 1: improving lipid profiles in high-fat-diet-treated rats. PLoS One: 2013; 8 e49976
39. Gaware R., Khunt R., Czollner L., Stanetty C., Cunha T. D., Kratschmar D. V., Odermatt A., Kosma P., Jordis U., Claen-Houben D. Synthesis of new glycyrrhetinic acid derived ring A azepanone, 29-urea and 29-hydroxamic acid derivatives as selective 11 β -hydroxysteroid dehydrogenase 2 inhibitors. Bioorg Med Chem: 2011; 19 1866 1880
40. Schweizer R. AS, Atanasov A. G., Frey B. M., Odermatt A. A rapid screening assay for inhibitors of 11 β -hydroxysteroid dehydrogenases (11 β -HSD): flavanone selectively inhibits 11 β -HSD1 reductase activity. Mol Cell Endocrinol: 2003; 212 41 49
41. Assimopoulou A. N., Ganzera M., Stuppner H., Papageorgiou V. P. Determination of penta- and tetra- cyclic triterpenes in Pistacia lentiscus resin. Planta Med: 2009; 75 PA37
42. Berman H. M., Westbrook J., Feng Z., Gilliland G., Bhat T. N., Weissig H., Shindayalov I. N., Bourne P. E. The Protein data bank. Nucleic Acids Res: 2000; 28 235 242
43. Wu X., Kavanagh K., Svensson S., Elleby B., Hult M., Von Delft F., Marsden B., Jornvall H., Abrahamsen L., Oppermann U. The high resolution structures of human, murine and guinea pig 11-beta-hydroxysteroid dehydrogenase type 1 reveal critical differences in active site architecture. 10.2210/pdb2bel/pdb Available online: http://www.rcsb.org/pdb/explore.do?structureId=2bel
44. Jones G., Willett P., Glen R. C., Leach A. R., Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol: 1997; 267 727 748
45. Verdonk M. L., Cole J. C., Hartshorn M. J., Murray C. W., Taylor R. D. Improved protein-ligand docking using GOLD. Proteins: 2003; 52 609 623